Platelet Derived Growth Factor in Treatment of Chronic Non Healing Ulcer: A 10 Year Journey

Read full text Summarise with VIRAT
Authors: Seema Shah, Neha Rani Verma, Shradha Verma, Suprava Patel, Rachita Nanda, Eli Mohapatra
Cited by: 0
References: 29

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: Chronic non-healing ulcers are a significant global healthcare burden, affecting about 8.2 million Medicare beneficiaries in the US, and costing an annual treatment cost of $28.1 to $96.8 billion annually. Platelet derived growth factor (PDGF) is a crucial hormone in wound healing that induces cell proliferation, angiogenesis, and extracellular matrix formation. This systematic review aims to assess the efficacy and safety of PDGF therapy versus placebo/usual care for chronic non-healing ulcers in the last 10 years. Methods: Systematic review according to the PRISMA 2020 statement by searching PubMed/MEDLINE, Scopus, Web of Science Cochrane Central Register of Controlled Trials and Embase from January 2015 to December 2024. Eligible studies were randomized controlled trials, cohort studies and case-control studies in adult patients with chronic non healing ulcers receiving PDGF preparations. The main outcome measures were complete healing rates, time to healing, ulcer area reduction and adverse events. The Cochrane Risk of Bias Tool was used for quality assessment. Results: There were 28 studies totaling 4,118 patients, including 3 retrospective cohorts, 7 prospective cohorts, and 18 randomized controlled trials. The majority of research concentrated on diabetic foot ulcers (71.4%), which were followed by pressure ulcers (10.7%) and venous leg ulcers (17.9%). When compared to standard care, platelet-derived growth factor (PDGF) dramatically increased healing rates, especially in venous leg ulcers (OR: 5.06) and diabetic foot ulcers (OR: 1.53). Additionally, PDGF increased the reduction of ulcer size and reduced the healing time by three to six weeks. Conclusion: PDGF therapy appears to be an effective and safe adjunctive treatment for chronic non-healing ulcers, particularly diabetic foot ulcers and venous leg ulcers. Its use is associated with improved healing rates, shorter healing time, and greater reduction in ulcer area compared with standard care. Future studies should focus on evaluating long-term outcomes, assessing cost-effectiveness, and identifying patient-specific predictors of treatment response in order to optimize its clinical use.

Fields of Study & Subjects

Wound Healing and Treatments Diabetic Foot Ulcer Assessment and Management Periodontal Regeneration and Treatments

Publication details

Journal / source
International Journal of Current Pharmaceutical Review and Research
Volume
18
Issue
03
Publication date
31 March 2026
Language
EN